

Appendix 3F

Final share buy-back notice (except minimum holding buy-back)

Introduced 1/9/99. Origin: Appendices 7D and 7E. Amended 30/9/2001, 11/01/10

Information and documents given to ASX become ASX's property and may be made public.

| | |
|--------------------------------|----------------|
| Name of entity | ABN/ARSN |
| Neuren Pharmaceuticals Limited | 72 111 496 130 |

We (the entity) give ASX the following information.

Description of buy-back

| | | |
|---|------------------|---|
| 1 | Type of buy-back | Buy-back from Neuren Trustee Limited of vested shares under the rules of employee Loan Funded Share Plan ("Plan") and in accordance with sections 61 and 62 of the New Zealand Companies Act 1993 |
|---|------------------|---|

Details of all shares/units bought back

| | | |
|---|--|---|
| 2 | Number of shares/units bought back | 501,607 |
| 3 | Total consideration paid or payable for the shares/units | \$1,560,000 (\$3.11 per share - VWAP for 5 days ending 29 May 2018) |
| 4 | If buy-back is an on-market buy-back - highest and lowest price paid | highest price: date: lowest price: date: |

+ See chapter 19 for defined terms.

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:

(Company secretary)

Date: 30 May 2018

Print name: Jon Pilcher

====